Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott v. Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Advanced Cardiovascular Solutions, a subsidiary of Abbott Laboratories formerly owned by Guidant, did not commit "inequitable conduct" to obtain stent technology that is also incorporated into Medtronic's S7 and Driver coronary stents, a U.S. District Court in Delaware rules April 24. The ruling completes the liability phase of a patent case originally brought by Guidant against Medtronic Vascular, although Medtronic says it will appeal (1"The Gray Sheet" March 21, 2005, p. 24). Medtronic also says that the decision does not impact the ongoing United States Patent and Trademark Office proceedings on the same patent. The USPTO is reexamining whether Guidant's so-called "Lau patents" are valid in light of Medtronic's claims of "prior art"...

You may also be interested in...

Medtronic, Abbott Settle Longstanding Stent IP Battles For $400 Mil.

Medtronic will pay Abbott Laboratories $400 million to resolve a costly series of global stent patent battles that have dragged on since the '90s and in some cases limited the companies' ability to commercialize in certain markets

Medtronic Gears For Stent Patent Infringement Showdowns With J&J, Guidant

Medtronic's Endeavor drug-eluting stent program and current coronary stent line-up are unaffected by a recent Johnson & Johnson patent infringement ruling against the company, Medtronic insists

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts